Skip to content
OpenCapital
Get started

Abbott ABT Established Pharmaceuticals — Selling, general, and administrative

Other segment segments

Medical Devices
$1.39B+7.8%
Nutritional Products
$563M-2.3%
Diagnostic Products
$448M+14.3%

Similar metrics at other companies

Vertex Pharmaceuticals logo
VRTXPharmaceuticals — Selling and other commercial expenses
$313.6M+30.1%
Agilent Technologies logo
ALife Sciences and Diagnostics Markets — Selling, General and Administrative Expense
$170M+8.3%
IQVIA logo
IQVOperating Segments — Selling General And Administrative Expense
$359M+12.5%
Biogen logo
BIIBReportable Segment — SG&A
$608.4M+1.2%
STERIS logo
STEHealthcare — Selling, general, and administrative
$170.5M+10.3%
Gilead Sciences logo
GILDReportable Segment — Selling and marketing expenses
$898M+19.3%

Other financials

Income statement

See full
Revenue$11.2B+7.8%
Gross profit$6.3B+6.5%
Operating income$1.3B-20.6%
Net income$1.1B-18.7%
EPS (diluted)$0.61-19.7%

Balance sheet

See full
Cash & equivalents$6.8B+4.2%
Total debt$34.0B+157%
Total equity$52.1B+6.7%
Total assets$110.43B+35.6%

Cash flow

See full
Operating cash flow$1.3B-7.2%
CapEx$399.0M-17.6%
Free cash flow$916.0M-1.8%

Valuation

See full
Market cap$154.15B-22.5%
Enterprise value$181.39B-13.1%
P/E24.6×+9.8×
P/S3.4×-1.3×

Profitability

See full
Gross margin56.3%+0.4pp
Operating margin17.1%+0.2pp
Net margin13.9%-18.0pp

Returns & leverage

See full
Return on equity12.4%-18.4pp
Debt / equity0.7×+0.4×
Current ratio1.4×-0.4×

Where this comes from

Reported directly by Abbott in its filing.

Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.

The official record: Abbott’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →

Ask your AI about Abbott's established pharmaceuticals — selling, general, and administrative.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Abbott's established pharmaceuticals — selling, general, and administrative?
Abbott (ABT) reported established pharmaceuticals — selling, general, and administrative of $376M in Q1 2026.
How has Abbott's established pharmaceuticals — selling, general, and administrative changed year-over-year?
Abbott's established pharmaceuticals — selling, general, and administrative increased by 7.1% year-over-year, from $351M to $376M.
What is the long-term trend for Abbott's established pharmaceuticals — selling, general, and administrative?
Over 3 years (2022 to 2025), Abbott's established pharmaceuticals — selling, general, and administrative has grown at a 2.0% compound annual growth rate (CAGR), from $1.37B to $1.46B.
What does established pharmaceuticals — selling, general, and administrative mean?
The total operating costs for sales, marketing, and administration within the segment.
How do you interpret established pharmaceuticals — selling, general, and administrative?
A lower ratio of SG&A to sales suggests improved operational efficiency and better cost management.
How does established pharmaceuticals — selling, general, and administrative compare across companies?
Standard SG&A expense reporting for business segments across all industries.